Progress of Chalcone Derivatives in Diagnosis and Treatment of Alzheimer's Disease

Alzheimer's disease (AD) is the most common chronic progressive neurodegenerative disease in elder people. At present, the pathogenesis of AD is still unclear. Due to the complex pathogenesis of AD, multi-target drugs are an important research direction for AD therapies. In addition, the development of imaging probes targeting amyloid β-protein (Aβ) plaque plays a key role in the early diagnosis of AD. Chalcone is a natural compound with diverse biological activities that deserves further development. According to the current literature, the development of chalcone and its derivatives into multi-target AD therapies and diagnostic Aβ imaging probes was summarized based on their activities on acetycholinesterase (AChE) inhibition, antioxidation, monoamine oxidase B (MAO-B) inhibition, Aβ aggregation inhibition, so as to provide useful information and theoretical basis for AD treatment and diagnosis.